Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Daily News

Top Heart Failure News of 2024

Todd Neale

December 31, 2024

News Daily News

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

Michael O'Riordan

December 06, 2024

News Conference News HFSA 2024

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

L.A. McKeown

October 02, 2024

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

July 2024 Dispatch for the CV Team

L.A. McKeown

July 01, 2024

News Conference News HRS 2024

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

Michael O'Riordan

May 23, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

Todd Neale

April 12, 2024

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

Advertisement

Top Heart Failure News of 2024

Sudden Cardiac Death in Athletes Is Rare, but Affects Black Population More

‘Global Efficacy’ of Aficamten for Obstructive Disease Shown in SEQUOIA-HCM

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

July 2024 Dispatch for the CV Team

Goal of Arrhythmia Care in Athletes is a Return to Play: HRS Consensus

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content